Statin use and risk of pancreatic cancer: a meta-analysis
- 700 Downloads
Statins are commonly prescribed medications that potently reduce cholesterol levels and the risk of cardiovascular events. Preclinical studies suggested statins also possess cancer chemopreventive properties. However, the clinical studies provided contradictory results as to whether statins influence the risk of pancreatic cancer. Herein, we present this meta-analysis to assess the association between statin use and risk of pancreatic cancer.
We conducted a comprehensive search up to August 2011 for the eligible studies. Pooled relative risk (RR) estimates and corresponding 95 % confidence intervals (CIs) were calculated using the inverse-variance-weighted random-effects model. Subgroup analyses were conducted where data were available. Heterogeneity was assessed by the Cochran’s Q test and the I2 statistic.
We included 16 studies that involving 1,692,863 participants and 7,807 pancreatic cancer cases. Pooled results only indicated a non-significant decrease of pancreatic cancer risk among all statin users (RR 0.89; 95 % CIs, 0.74–1.07). Similar results were obtained in the subgroup analyses of the long-term (more than 4 years) follow-up (RR 0.94, 0.81–1.08) and statin use (RR 0.97, 0.76–1.23), and a null association was found between lipophilic statin use and pancreatic cancer risk (RR 1.03, 0.92–1.16). No evidence of publication bias was observed in the present meta-analysis. However, significant heterogeneity was detected among all studies (p < 0.00001, I2 = 81 %).
In conclusion, our results suggest that there is no association between statin use and pancreatic cancer risk, when statins are taken at daily doses for cardiovascular event prevention.
KeywordsStatin Pancreatic cancer Risk Prevention Meta-analysis
Randomized controlled trials
We would like to thank Gui Lv (Senior Lecturer in School of Foreign Studies, Southern Medical University) for her constructive comments and careful revision of this manuscript.
Conflict of interest
There are no potential conflicts of interest among all authors.
- 3.Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493):1267–1278. doi:10.1016/S0140-6736(05)67394-1 PubMedCrossRefGoogle Scholar
- 9.Kusama T, Mukai M, Iwasaki T, Tatsuta M, Matsumoto Y, Akedo H, Nakamura H (2001) Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors. Cancer Res 61(12):4885–4891PubMedGoogle Scholar
- 17.Bonovas S, Filioussi K, Sitaras NM (2008) Statins are not associated with a reduced risk of pancreatic cancer at the population level, when taken at low doses for managing hypercholesterolemia: evidence from a meta-analysis of 12 studies. Am J Gastroenterol 103(10):2646–2651. doi:10.1111/j.1572-0241.2008.02051.x PubMedCrossRefGoogle Scholar
- 20.Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 283(15):2008–2012PubMedCrossRefGoogle Scholar
- 24.Higgins JP, Green S (2011) Cochrane handbook for systematic reviews of interventions. http://www.cochrane-handbook.org/
- 25.Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P (2012) The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
- 27.Midgette AS, Wong JB, Beshansky JR, Porath A, Fleming C, Pauker SG (1994) Cost-effectiveness of streptokinase for acute myocardial infarction: a combined meta-analysis and decision analysis of the effects of infarct location and of likelihood of infarction. Med Decis Making 14(2):108–117PubMedCrossRefGoogle Scholar
- 31.Clearfield M, Downs JR, Weis S, Whitney EJ, Kruyer W, Shapiro DR, Stein EA, Langendorfer A, Beere PA, Gotto AM (2001) Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women. J Women’s Health Gender Based Med 10(10):971–981. doi:10.1089/152460901317193549 CrossRefGoogle Scholar
- 32.Serruys PW, de Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, Branzi A, Bertolami MC, Jackson G, Strauss B, Meier B (2002) Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 287(24):3215–3222PubMedCrossRefGoogle Scholar
- 33.Strandberg TE, Pyorala K, Cook TJ, Wilhelmsen L, Faergeman O, Thorgeirsson G, Pederson TR, Kjekshus J (2004) Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 364(9436):771–777. doi:10.1016/s0140-6736(04)16936-5 PubMedCrossRefGoogle Scholar
- 35.Marelli C, Gunnarsson C, Ross S, Haas S, Stroup DF, Cload P, Clopton P, DeMaria AN (2011) Statins and risk of cancer a retrospective cohort analysis of 45,857 matched pairs from an electronic medical records database of 11 million adult Americans. J Am Coll Cardiol 58(5):530–537. doi:10.1016/j.jacc.2011.04.015 PubMedCrossRefGoogle Scholar
- 40.Pugh TE, Little MW, Carey FJ, Robinson RJ, Clark A, Metcalfe M, Ndokera R, Ing H, Dennison A, Hart A (2011) Aspirin, NSAIDS, calcium-channel blockers and statins in the aetiology of pancreatic cancer: preliminary results from a case-control study in two centres in the UK. Gut 60(Suppl 1):A81. doi:10.1136/gut.2011.239301.166 CrossRefGoogle Scholar
- 41.Dorais M TR, Rakel A, Lelorrier J, Panzini B (2007) Statins, nsaids and pancreatic cancer. Paper presented at the 4th Canadian therapeutics congress, Halifax, Nova Scotia, 10 May 2007. http://www.cjcp.ca/pubmed.php?articleId=113
- 48.Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376(9753):1670–1681. doi:10.1016/s0140-6736(10)61350-5 PubMedCrossRefGoogle Scholar
- 53.Trial of Simvastatin and Gemcitabine in Pancreatic Cancer Patients (2012) http://clinicaltrials.gov/ct2/show/NCT00944463